Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IARS1 | P41252 | 5/20 | 0.69 |
| ▸ | HTR2A | P28223 | 1/20 | 0.69 |
| ▸ | PTGFR | P43088 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14616862 | 1.00 | IARS1 (0.69) | IARS1HTR2APTGFR | |
| SCHEMBL14045603 | 0.87 | IARS1 (0.66) | IARS1HTR2A | |
| SCHEMBL29885016 | 0.84 | IARS1 (0.51) | IARS1HTR2A | |
| SCHEMBL29885136 | 0.84 | IARS1 (0.51) | IARS1HTR2A | |
| SCHEMBL19183608 | 0.82 | IARS1 (0.69) | IARS1HTR2A | |
| SCHEMBL9033558 | 0.82 | HTR2A (0.44) | IARS1HTR2A | |
| Mupirocin SCHEMBL15387504 | 0.82 | IARS1 (1.00) | IARS1HTR2A | |
| Mupirocin SCHEMBL18995884 | 0.82 | IARS1 (1.00) | IARS1HTR2A | |
| Mupirocin SCHEMBL1027616 | 0.82 | IARS1 (1.00) | IARS1HTR2A | |
| Mupirocin SCHEMBL3291 | 0.82 | IARS1 (1.00) | IARS1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015413-A1 | PROCESS FOR PREPARING CRYSTALLINE CALCIUM MUPIROCIN DIHYDRATE | DEFTERDAROVIC NAFIS | 2011-01-20 | — | — | US | claimed |
| WO-2009092991-A1 | PROCESS FOR PREPARING CRYSTALLINE CALCIUM MUPIROCIN DIHYDRATE | PLIVA HRVATSKA D.O.O. (HR) | 2009-07-30 | — | — | WO | claimed |
| CN-1126493-A | Enzymatic preparation of monic acids | SMITHKLINE BEECHAM PLC (GB) | 1996-07-10 | — | — | CN | claimed |
| EP-0707657-A1 | ENZYMATIC PREPARATION OF MONIC ACIDS | SMITHKLINE BEECHAM PLC (GB) | 1996-04-24 | — | — | EP | claimed |
| WO-1995002064-A1 | ENZYMATIC PREPARATION OF MONIC ACIDS | SMITHKLINE BEECHAM PLC (GB) | 1995-01-19 | — | — | WO | claimed |
| EP-0003069-B1 | PSEUDOMONIC ACID C, PHARMACEUTICALLY ACCEPTABLE SALTS OR ESTERS THEREOF, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL OR VETERINARY COMPOSITIONS CONTAINING THEM | BEECHAM GROUP PLC (GB) | 1981-05-20 | — | — | EP | claimed |
| US-4226880-A | PSEUDOMONIC ACID C AND DERIVATIVES | BEECHAM GROUP LIMITED (GB) | 1980-10-07 | — | — | US | claimed |
| US-4205002-A | PSEUDOMONIC ACID C AND DERIVATIVES | BEECHAM GROUP LIMITED (GB) | 1980-05-27 | — | — | US | claimed |
| EP-0003069-A1 | Pseudomonic acid C, pharmaceutically acceptable salts or esters thereof, processes for their preparation and pharmaceutical or veterinary compositions containing them | BEECHAM GROUP PLC (GB) | 1979-07-25 | — | — | EP | claimed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| CN-108277243-B | Preparation method of pseudomonic acid A | 浙江瑞邦药业股份有限公司 | 2021-03-12 | — | — | CN | disclosed |
| CN-111220721-A | Mupirocin ointment impurity qualitative positioning and testing method and application | 湖北人福成田药业有限公司 | 2020-06-02 | — | — | CN | disclosed |
| US-20190309289-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10370654-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-4205002-A | PSEUDOMONIC ACID C AND DERIVATIVES | BEECHAM GROUP LIMITED (GB) | 1980-05-27 | — | — | US | disclosed |
| EP-0005006-A2 | Antibacterial monic acid C derivatives, processes for their preparation and compositions containing them | BEECHAM GROUP PLC (GB) | 1979-10-31 | — | — | EP | disclosed |
| EP-0005006-A2 | Antibacterial monic acid C derivatives, processes for their preparation and compositions containing them | BEECHAM GROUP PLC (GB) | 1979-10-31 | — | — | EP | disclosed |
| EP-0003069-A1 | Pseudomonic acid C, pharmaceutically acceptable salts or esters thereof, processes for their preparation and pharmaceutical or veterinary compositions containing them | BEECHAM GROUP PLC (GB) | 1979-07-25 | — | — | EP | disclosed |
| EP-0003069-A1 | Pseudomonic acid C, pharmaceutically acceptable salts or esters thereof, processes for their preparation and pharmaceutical or veterinary compositions containing them | BEECHAM GROUP PLC (GB) | 1979-07-25 | — | — | EP | disclosed |
| EP-0003069-A1 | Pseudomonic acid C, pharmaceutically acceptable salts or esters thereof, processes for their preparation and pharmaceutical or veterinary compositions containing them | BEECHAM GROUP PLC (GB) | 1979-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015413-A1 | PROCESS FOR PREPARING CRYSTALLINE CALCIUM MUPIROCIN DIHYDRATE | CACYBP, CAPRIN1, PRCP | IARS1 4569/4885HTR2A 3039/4885PTGFR 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.